[go: up one dir, main page]

MA31924B1 - Derives d'oxadiazole actifs sur la sphingosine-1-phosphate (s1p) - Google Patents

Derives d'oxadiazole actifs sur la sphingosine-1-phosphate (s1p)

Info

Publication number
MA31924B1
MA31924B1 MA32926A MA32926A MA31924B1 MA 31924 B1 MA31924 B1 MA 31924B1 MA 32926 A MA32926 A MA 32926A MA 32926 A MA32926 A MA 32926A MA 31924 B1 MA31924 B1 MA 31924B1
Authority
MA
Morocco
Prior art keywords
sphingosine
phosphate
active
alkyl group
hydrogen atom
Prior art date
Application number
MA32926A
Other languages
Arabic (ar)
English (en)
Inventor
Emmanuel Hubert Demont
Jag Paul Heer
Thomas Daniel Heightman
David Nigel Hurst
Christopher Norbert Johnson
John Skidmore
Ian David Wall
Jason Witherington
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0725120A external-priority patent/GB0725120D0/en
Priority claimed from GB0821918A external-priority patent/GB0821918D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA31924B1 publication Critical patent/MA31924B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention concerne des composés à base d'oxadiazole de formule (i) actifs sur la sphingosine-1-phosphate (s1p), en particulier utiles pour traiter le lupus érythémateux. A est un groupe phényle ou un cycle hétéroaryle à 5 ou 6 chaînons; r1 représente jusqu'à deux substituants indépendamment choisis parmi un atome d'halogène, un groupe alcoxy en c1-3, fluoroalkyle en c1-3, cyano, phényle éventuellement substitué, un groupe fluoroalkoxy en c1-3, alkyle en c1-6 et cycloalkyle en c3-6; r2 est un atome d'hydrogène, un atome d'halogène ou un groupe alkyle en c1-4; b est un cycle saturé à 7 chaînons choisi parmi : formules (a) (b) (c); r3 est un atome d'hydrogène ou (ch2)1-4mco2h; r4 est un atome d'hydrogène ou groupe alkyle en c1-3 éventuellement interrompu par un atome d'oxygène
MA32926A 2007-12-21 2010-06-16 Derives d'oxadiazole actifs sur la sphingosine-1-phosphate (s1p) MA31924B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0725120A GB0725120D0 (en) 2007-12-21 2007-12-21 Compounds
GB0821918A GB0821918D0 (en) 2008-12-01 2008-12-01 Compounds
PCT/EP2008/067965 WO2009080725A1 (fr) 2007-12-21 2008-12-19 Dérivés d'oxadiazole actifs sur la sphingosine-1-phosphate (s1p)

Publications (1)

Publication Number Publication Date
MA31924B1 true MA31924B1 (fr) 2010-12-01

Family

ID=40342566

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32926A MA31924B1 (fr) 2007-12-21 2010-06-16 Derives d'oxadiazole actifs sur la sphingosine-1-phosphate (s1p)

Country Status (28)

Country Link
US (2) US8222245B2 (fr)
EP (1) EP2222669B1 (fr)
JP (1) JP2011506569A (fr)
KR (1) KR20100108566A (fr)
CN (1) CN101945863B (fr)
AR (1) AR069916A1 (fr)
AU (1) AU2008339988B2 (fr)
BR (1) BRPI0820131A2 (fr)
CA (1) CA2710130A1 (fr)
CO (1) CO6290646A2 (fr)
CR (1) CR11579A (fr)
DK (1) DK2222669T3 (fr)
DO (1) DOP2010000194A (fr)
EA (1) EA017691B1 (fr)
ES (1) ES2434730T3 (fr)
HR (1) HRP20130957T1 (fr)
IL (1) IL206235A0 (fr)
MA (1) MA31924B1 (fr)
NZ (1) NZ585996A (fr)
PE (1) PE20091339A1 (fr)
PL (1) PL2222669T3 (fr)
PT (1) PT2222669E (fr)
RS (1) RS53038B (fr)
SI (1) SI2222669T1 (fr)
TW (1) TWI415847B (fr)
UY (1) UY31570A1 (fr)
WO (1) WO2009080725A1 (fr)
ZA (1) ZA201003963B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
PE20091057A1 (es) 2007-12-19 2009-07-20 Lilly Co Eli Antagonistas del receptor mineralcorticoide y metodos de uso
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
GB0725105D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725102D0 (en) * 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725101D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
GB0807910D0 (en) 2008-04-30 2008-06-04 Glaxo Group Ltd Compounds
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
NZ594172A (en) 2008-12-22 2013-04-26 Merck Patent Gmbh Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{ 3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl} -2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
GB0910674D0 (en) 2009-06-19 2009-08-05 Glaxo Group Ltd Novel compounds
WO2011028927A1 (fr) * 2009-09-04 2011-03-10 Allergan, Inc. Antagonistes sélectifs des récepteurs de sphingosine-1-phosphate
TWI577670B (zh) 2011-05-10 2017-04-11 基利科學股份有限公司 充當離子通道調節劑之稠合雜環化合物
CN102250035A (zh) * 2011-06-10 2011-11-23 北京富卡生物技术有限公司 二芳基取代-1，3，4-噁二唑化合物的合成方法和其药物用途
NO3175985T3 (fr) 2011-07-01 2018-04-28
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
RU2543485C2 (ru) * 2013-02-26 2015-03-10 Андрей Александрович Иващенко Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
CN104844535A (zh) * 2014-02-13 2015-08-19 吉利德科学公司 用于制备稠合杂环离子通道调节剂的方法
TWI689487B (zh) 2014-08-20 2020-04-01 美商必治妥美雅史谷比公司 經取代雙環化合物
US10183940B2 (en) * 2014-11-14 2019-01-22 Boehringer Ingelheim International Gmbh Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (SSTR4) agonists
CA2963447A1 (fr) * 2014-12-01 2016-06-09 Actelion Pharmaceuticals Ltd Modulateurs du recepteur cxcr7
US20250179084A1 (en) * 2021-02-10 2025-06-05 Icahn School Of Medicine At Mount Sinai OXADIAZOLYL DIHYDROPYRANO[2,3-b]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS
WO2023081328A1 (fr) * 2021-11-04 2023-05-11 Valo Health, Inc. Composés inhibiteurs d'histone désacétylase 6 et leurs utilisations

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
AU2303402A (en) 2000-11-14 2002-05-27 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
JP2005533058A (ja) 2002-06-17 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート
AU2004249664A1 (en) * 2003-05-19 2004-12-29 Irm Llc Immunosuppressant compounds and compositions
AU2004277947A1 (en) * 2003-10-01 2005-04-14 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists
WO2005058848A1 (fr) 2003-12-17 2005-06-30 Merck & Co., Inc. Carboxylates propanoiques 3,4-disusbstitues utilises en tant qu'agonistes du recepteur s1p (edg)
US8039674B2 (en) * 2004-06-23 2011-10-18 Ono Pharmaceutical Co., Ltd. Compound having S1P receptor binding potency and use thereof
GB0414795D0 (en) 2004-07-01 2004-08-04 Glaxo Group Ltd Compounds
AU2005299851B2 (en) 2004-10-22 2011-03-17 Merck Sharp & Dohme Corp. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
AU2005314938B2 (en) 2004-12-13 2011-06-09 Ono Pharmaceutical Co., Ltd. Aminocarboxylic acid derivative and medicinal use thereof
MX2007011670A (es) * 2005-03-23 2007-11-15 Actelion Pharmaceuticals Ltd Derivados de benzo(c) tiofeno hidrogenados como inmunomoduladores.
RU2404178C2 (ru) 2005-03-23 2010-11-20 Актелион Фармасьютиклз Лтд Новые производные тиофена в качестве агонистов рецептора сфингозин-1-фосфата-1
CA2605594A1 (fr) * 2005-04-22 2006-11-02 Daiichi Sankyo Company, Limited Compose heterocyclique
WO2006131336A1 (fr) * 2005-06-08 2006-12-14 Novartis Ag Oxadiazoles polycycliques ou soxazoles i et leur utilisation comme ligands recepteurs de s1p
CA2619101A1 (fr) 2005-08-23 2007-03-01 Irm Llc Composes immunosuppresseurs et compositions associees
AR058221A1 (es) 2005-11-24 2008-01-23 Glaxo Group Ltd Benzazepinas inhibidoras del factor xa, composicion farmaceutica que la comprende y su uso para fabricar un medicamento
MX2008012738A (es) * 2006-04-03 2009-02-06 Astellas Pharma Inc Heterocompuesto.
AU2007323557A1 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
GB0725104D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725102D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725101D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725105D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
SI2222669T1 (sl) 2013-10-30
EA017691B1 (ru) 2013-02-28
AR069916A1 (es) 2010-03-03
CA2710130A1 (fr) 2009-07-02
EP2222669A1 (fr) 2010-09-01
KR20100108566A (ko) 2010-10-07
AU2008339988B2 (en) 2013-09-26
ZA201003963B (en) 2011-11-30
BRPI0820131A2 (pt) 2015-05-12
CN101945863A (zh) 2011-01-12
PT2222669E (pt) 2013-10-28
IL206235A0 (en) 2010-12-30
UY31570A1 (es) 2009-05-29
CR11579A (es) 2010-09-03
JP2011506569A (ja) 2011-03-03
TW200940531A (en) 2009-10-01
EP2222669B1 (fr) 2013-08-21
PL2222669T3 (pl) 2014-01-31
CO6290646A2 (es) 2011-06-20
DOP2010000194A (es) 2010-08-15
NZ585996A (en) 2012-06-29
US8222245B2 (en) 2012-07-17
EA201070782A1 (ru) 2010-12-30
TWI415847B (zh) 2013-11-21
US20100174065A1 (en) 2010-07-08
ES2434730T3 (es) 2013-12-17
CN101945863B (zh) 2013-07-03
PE20091339A1 (es) 2009-09-26
RS53038B (sr) 2014-04-30
AU2008339988A1 (en) 2009-07-02
WO2009080725A1 (fr) 2009-07-02
HRP20130957T1 (hr) 2013-11-08
US20100273771A1 (en) 2010-10-28
DK2222669T3 (da) 2013-10-28
HK1142062A1 (en) 2010-11-26

Similar Documents

Publication Publication Date Title
MA31924B1 (fr) Derives d'oxadiazole actifs sur la sphingosine-1-phosphate (s1p)
DE60137405D1 (de) Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente
ATE293101T1 (de) Piperidine zur verwendung als orexin rezeptor antagonisten
HUP0303164A2 (hu) Kinazolinok mint MMP-13 gátlók, eljárás az előállításukra, intermedierjeik és a vegyületeket tartalmazó gyógyszerkészítmények
DE69503803D1 (de) 3,5-dioxo-(2h,4h)-1,2,4-triazinderivate ihre herstellung und verwendung als medikament
MY142807A (en) Benzimidazole derivative and use thereof.
MA31674B1 (fr) Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique
RU2012130959A (ru) Фенольные производные и их фармацевтическое или косметическое применение
EA200401613A1 (ru) Лекарственное средство для лечения рака
MY146646A (en) 2,3-dihydro-6-nitroimidazo [2,1-b] oxazole compounds for the treatment of tuberculosis
RU2009133453A (ru) Фторсодержащее пиразолкарбонитрильное производное и способ его получения и фторсодержащее производное пиразолкарбоновой кислоты, полученное с применением фторсодержащего пиразолкарбонитрильного производного и способ его получения
RU2010100971A (ru) Аминосоединение и его фармацевтическое применение
RU2010101004A (ru) Новые микробиоциды
MA32642B1 (fr) Amides utiles en therapie
PH12015501098A1 (en) Antituberculous composition comprising oxazole compounds
MA35133B1 (fr) Dérivés d'éthynyle comme modulateurs allostériques positifs de mglur5
MA35113B1 (fr) 5-(phényl/pyridinyl-éthinyl)-2-pyridine/2 pyrimidine-carboxamides comme modulateur de mglur5
MA31922B1 (fr) Dérivés d'oxadiazole actifs sur la sphingosine-1-phosphate (s1p)
MA38885B1 (fr) Dérivés d'éthynyle modulateurs allosteriques positifs (pam) du recepteur metabotropique du glutamate 4 (mglu4)
ATE550332T1 (de) 4-imidazolin-2-onverbindungen als p38-map- kinaseinhibitors
BR0308759A (pt) Derivados de fenil amidas siliconadas utilizáveis como microbiocida
PH12021551133A1 (en) N-(4-(oxazol-5-yl)phenyl)chromane-3-carboxamide derivatives and related compounds as stimulators of the production of retinal precursor cells for the treatment of neuroretinal diseases
ATE301125T1 (de) Heterocyclische verbindungen und mittel, die die hirnfunktion verbessern und als wirkstoff diese verbindungen enthalten
TR200402494T4 (tr) Mantar öldürücü 6-(2-triflorometil-fenil)-triazolopirimidinler.
ATE348818T1 (de) Cyclische hydroxylamine als psychoactive verbindugen